中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

2018 No. 4

Display Method:
Editorial
Current status and perspectives of integrated traditional Chinese and Western medicine therapy for common hepatobiliary and pancreatic diseases
Wang RongBing, Sun FengXia
2018, 34(4): 683-688. DOI: 10.3969/j.issn.1001-5256.2018.04.001
Abstract:
At present, the diagnosis and treatment with integrated traditional Chinese and Western medicine takes the form of traditional Chinese medicine treatment or the combination of traditional Chinese medicine and Western medicine, with the application of modern diagnostic and therapeutic evaluation methods.Although there lacks theoretical breakthrough, more and more consensus statements and innovations have been accumulated in clinical practice and scientific research.This article introduces the current status of clinical practice and research in the treatment of common hepatobiliary and pancreatic diseases in the past 10 years and collects the articles with a definite diagnosis, major scientific research projects, and evidence of evidence-based medicine which are published in core journals.We aim to objectively reflect the advantages and effects of integrated traditional Chinese and Western medicine therapy for hepatobiliary and pancreatic diseases, in order to provide new inspirations for clinical practice and scientific research in this field.
Discussions by experts
The role of traditional Chinese medicine in blocking and reversing hepatic fibrosis:current status, hope, and challenge
Chen Yan, Yang YongPing
2018, 34(4): 689-693. DOI: 10.3969/j.issn.1001-5256.2018.04.002
Abstract:

Traditional Chinese medicine (TCM) syndrome differentiation-based treatment has certain advantages in blocking and reversing hepatic fibrosis and is the source of candidate drugs for hepatic fibrosis in future.This article overviews the origin and current status of TCM treatment of hepatic fibrosis, discusses how to reevaluate the clinical effect and safety of TCM in blocking and reversing hepatic fibrosis in accordance with evidence-based medicine and internationally acknowledged standards for clinical trials, and introduces the latest clinical research findings.It also emphasizes the challenge and significance of the exploration and recognition of TCM in blocking and reversing hepatic fibrosis.

Traditional Chinese medicine prevention and treatment of liver fibrosis under the new situation of prevention and treatment of viral hepatitis
Chi XiaoLing, Xiao HuanMing
2018, 34(4): 694-697. DOI: 10.3969/j.issn.1001-5256.2018.04.003
Abstract:

The prevention and treatment of liver fibrosis is an important embodiment of the characteristic advantage of traditional Chinese medicine (TCM) in the prevention and treatment of viral hepatitis.The release of Global Health Sector Strategy on Viral Hepatitis, 2016-2021 and Viral Hepatitis Prevention and Control Plan of China (2017-2020) brings opportunities to TCM prevention and treatment of liver fibrosis.There are still challenges in the research on TCM prevention and treatment of liver fibrosis, including how to improve the outcome of liver fibrosis and the research and development of more effective TCM new drugs for liver fibrosis.With the purpose of improving the clinical effect, we will start from the different stages of the development and progression of liver fibrosis, use the advantages of TCM syndrome differentiation-based treatment, provide early intervention, conduct clinical and basic research with the combination of precision medicine and TCM management of chronic diseases, and further establish and promote the application of the guidelines for clinical diagnosis and treatment of liver fibrosis and the TCM management guidelines for chronic diseases, which are the important contents of TCM prevention and treatment of liver fibrosis in future.

Research advances in integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis
Zhang Wei
2018, 34(4): 698-703. DOI: 10.3969/j.issn.1001-5256.2018.04.004
Abstract:
This article reviews the etiology and pathogenesis of primary biliary cholangitis (PBC) based on traditional Chinese and Western medicine, integrated traditional Chinese and Western medicine therapies and their clinical effects, and the author's experience in PBC research.The risk of PBC is closely associated with environmental factors, genetic factors, autoimmunity, and biliary epithelial cell injury.The analysis of etiology based on traditional Chinese medicine (TCM) showed that PBC is associated with " deficiency", " stasis", " depression", " dampness", and " toxin", and the key words of etiology and pathogenesis are damp-heat, blood stasis, stagnation of liver qi, qi stagnation, spleen-qi deficiency, liver-qi deficiency, and liver-kidney yin deficiency.Common TCM syndrome types include damp-heat accumulation, stagnation of liver qi and spleen deficiency, blood stasis obstructing the collaterals, and liver-kidney yin deficiency.Ursodeoxycholic acid is the first-line drug for the treatment of PBC, but 40% of patients have poor response.A combination of traditional Chinese medicine and Western medicine plays an important role in improving quality of life, prolonging survival time, and improving the clinical outcome of patients with PBC.
Current status and perspectives of integrated traditional Chinese and Western medicine therapy for chololithiasis
Feng Jian, Cui NaiQiang
2018, 34(4): 704-709. DOI: 10.3969/j.issn.1001-5256.2018.04.005
Abstract:
Chololithiasis has a high incidence rate, and at present, cholecystectomy has become the standard method for the treatment of gallstones.Traditional Chinese medicine treatment has a long history in the treatment of chololithiasis and has accumulated rich experience.This article summarizes the clinical effect of integrated traditional Chinese and Western medicine therapy in treating cholecystitis, controlling biliary tract infection, regulating bile metabolism, and preventing stenosis and recurrence of calculus after bile duct surgery, in order to provide experience for the development of individualized and accurate treatment regimens for patients with gallstones.
Early traditional Chinese medicine treatment of acute pancreatitis and its mechanism
Yang GuoHong, Zhao WenXia
2018, 34(4): 710-715. DOI: 10.3969/j.issn.1001-5256.2018.04.006
Abstract:

Traditional Chinese medicine (TCM) plays an important role in the treatment of acute pancreatitis (AP) .This article introduces the clinical effects of TCM treatments including gavage, enema, external application of Chinese medicine, intravenous drip, and acupuncture, and points out that early application of Chinese medicine for AP can help alleviate clinical symptoms and signs, reduce complications, and decrease mortality.Combined treatment based on staging and syndrome differentiation is considered more effective for AP.It is suggested that TCM treatment plays a therapeutic role by reducing inflammatory cytokines, improving intestinal function and barrier, regulating immune function, and improving blood circulation to block the progression of inflammation.

Therapeutic guidelines
Chinese expert consensus on treatment of pancreatic cancer by radioactive 125I particle implantation (2017)
Committee of Experts on Radioactive Particle Implantation Technology, Chinese Medical Doctor Association; Particle Treatment Branch, Committee of Minimally Invasive Therapy in Oncology, Chinese Anti-cancer Association
2018, 34(4): 716-723. DOI: 10.3969/j.issn.1001-5256.2018.04.007
Abstract:
Clinical practice guidelines for the interventional treatment of advanced pancreatic carcinoma (on trial) (2nd edition)
Committee of Interventional Medicine, Cancer Foundation of China
2018, 34(4): 724-736. DOI: 10.3969/j.issn.1001-5256.2018.04.008
Abstract:
An excerpt of update on prevention, diagnosis, and treatment  of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Zhang JingQiao, Li MiaoMiao, Qi XingShun, Ceng QingLei
2018, 34(4): 737-742. DOI: 10.3969/j.issn.1001-5256.2018.04.009
Abstract:
Zhang Hong, Zhang Hao, Liu Li, Jiang JianXin
2018, 34(4): 743-748. DOI: 10.3969/j.issn.1001-5256.2018.04.010
Abstract:
An excerpt of treatment of chronic hepatitis C virus infection in children. A position paper by the Hepatology Committee of ESPGHAN
Wang Shuai, Han JuQiang, Wen Wei
2018, 34(4): 749-754. DOI: 10.3969/j.issn.1001-5256.2018.04.011
Abstract:
Original articles_Viral hepatitis
Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B
Yao MingJie, Wang LeiJie, Guan GuiWen, Xi JingYuan, Liu ShuHong, Wen XiaJie, Zou Jun, Chen XiangMei, Jia JiDong, Zhao JingMin, Lu FengMin
2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012
Abstract:
Objective To investigate the value of Golgi protein 73 (GP73) in the diagnosis of liver inflammatory activity and fibrosis degree in chronic hepatitis B (CHB) patients.Methods Serum samples were collected from 678 patients who underwent liver biopsy in 302 Hospital of PLA from December 2013 to May 2017, and the patients were randomly divided into group A with 477 patients and group B with 201 patients.A double-antibody sandwich ELISA kit was used to measure the serum level of GP73 according to instructions.The Mann-Whitney U test was used for the comparison of two independent samples, the Spearman correlation analysis was used to investigate correlation, and the chi-square test was used for comparison of categorical data between groups.Results The serum level of GP73 increased with increasing liver inflammatory activity and fibrosis degree in both groups; in group A, the serum level of GP73 was significantly correlated with liver inflammatory activity and fibrosis degree (r = 0.529 and 0.434, both P < 0.001) , and a similar result was obtained in group B (r =0.418 and 0.437, both P < 0.001) .The areas under the receiver operating characteristic curve of serum GP73 to diagnose G≥2 liver inflammation and necrosis and G≥3 inflammation and necrosis were 0.774 (95% confidence interval [CI]:0.733-0.811, P < 0.001) and0.844 (95% CI:0.808-0.875, P < 0.001) in group A and 0.730 (95% CI:0.663-0.790, P < 0.001) and 0.716 (95% CI:0.649-0.777, P < 0.001) in group B.With the help of alanine aminotransferase (ALT) combined with serum GP73, 77.4% of the patients in group A and 78.9% of the patients in group B were found to have G≥2 and/or S≥2 disease.Conclusion Serum GP73 can be used in combination with ALT to identify the CHB patients that need antiviral therapy and thus reduce the dependence on liver biopsy.
Original articles_Liver fibrosis and liver cirrhosis
Value of serum adenosine deaminase in diagnosis of marked liver fibrosis in patients with chronic hepatitis B virus infection
Ke YeFang, Gao GuoSheng, Zhu Zhe, Chen BiCheng
2018, 34(4): 760-763. DOI: 10.3969/j.issn.1001-5256.2018.04.013
Abstract:
Objective To investigate the value of serum adenosine deaminase (ADA) in the diagnosis of marked liver fibrosis in patients with chronic hepatitis B virus (HBV) infection.Methods A total of 493 patients with chronic HBV infection who underwent liver biopsy in Ningbo No.2 Hospital from May 2011 to October 2016 were enrolled, and according to the degree of liver fibrosis, these patients were divided into S0 group with 79 patients, S1 group with 254 patients, S2 group with 103 patients, S3 group with 35 patients, and S4 group with 22 patients.Biochemical parameters including total bilirubin (TBil) , alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , gamma-glutamyl transpeptidase (GGT) , albumin (Alb) , and ADA were measured, routine blood test was performed, and aspartate aminotransferase-to-platelet ratio index (APRI) was calculated.These indices were compared between groups.An analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the Kruskal-Wallis H test was used for comparison of continuous data with skewed distribution between groups.The chi-square test was used for comparison of categorical data between groups.A dichotomous logistic regression analysis was performed for these indices, and the receiver operating characteristic (ROC) curve was used to analyze the value of ADA, APRI, or a combination of various indices in the diagnosis of marked liver fibrosis.Results There were significant differences in age, sex, TBil, ALT, AST, alkaline phosphatase, GGT, Alb, ADA, and APRI between the S0, S1, S2, S3, and S4 groups (F = 11.41, χ2= 14.45, 15.08, 28.27, 48.22, 48.65, 80.53, 17.03, 57.89, and 73.20, all P < 0.05) .Sex, age, and serum ADA were independent risk factors for marked liver fibrosis (odds ratio = 2.59, 1.05, and 1.12, all P < 0.01) .ADA, APRI, or a combination of various indices had a certain value in the diagnosis of marked liver fibrosis (all P < 0.01) , with an area under the ROC curve of 0.70, 0.73, and 0.75, respectively.Conclusion Serum ADA has a certain value in the diagnosis of marked liver fibrosis in patients with chronic HBV infection.
Value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein in predicting fibrosis degree in patients with chronic viral hepatitis
Gao Min, Liu Rong, Zhang Qing
2018, 34(4): 764-769. DOI: 10.3969/j.issn.1001-5256.2018.04.014
Abstract:
Objective To investigate the clinical value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) in predicting fibrosis degree in patients with chronic viral hepatitis.Methods A total of 98 patients with chronic hepatitis B (CHB group) and 104 patients with chronic hepatitis C (CHC group) , who were admitted to Hanzhong Municipal Hospital from March 2015 to June 2016 and underwent liver biopsy, were enrolled, and 56 healthy subjects were enrolled as control group.Quantitative real-time PCR was used to measure the serum level of miRNA-122 for all groups, and HISCL M2BPGi was used to measure the serum level of WFA+-M2BP.The t-test was used for comparison of continuous data between groups and the chi-square test was used for comparison of categorical data between groups.The receiver operating characteristic (ROC) curve was used to analyze the value of serum miRNA-122 and WFA+-M2BP in predicting fibrosis degree in patients with hepatitis, and the logistic regression model was used to perform multivariate analysis and predict probability.Results Compared with the control group, the CHB group and the CHC group had significantly higher serum levels of miRNA-122 (t = 39.437 and 11.460, P < 0.001 and P = 0.005) and WFA+-M2BP (t = 12.885 and 18.500, P = 0.004 and 0.002) .In the CHB group, the patients with S1-2 fibrosis had a significantly higher serum level of miRNA-122 than those with S3-4 fibrosis (t = 11.795, P = 0.006) .In the CHB group and the CHC group, the patients with S1-2 fibrosis and G1-2 liver inflammatory activity had a significantly lower serum level of WFA+-M2BP than those with S3-4 fibrosis (t = 8.584 and 3.565, P = 0.016 and 0.031) and G3-4 liver inflammatory activity (t = 5.568 and 3.354, P = 0.022 and 0.048) .The ROC curve analysis showed that miRNA-122 and WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHB patients, while WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHC patients (P < 0.05) ; miRNA-122 combined with WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHB and CHC patients (area under the ROC curve > 0.9, all P = 0.001) .Conclusion Serum miRNA-122 combined with WFA+-M2BP can be used to predict fibrosis degree in both CHB and CHC patients.
An investigation of minimal hepatic encephalopathy in patients with hepatitis B cirrhosis
Zhang LiJie, Zhou YingXia, Xing HuiChun, Su Ye, Sun YuMei
2018, 34(4): 770-774. DOI: 10.3969/j.issn.1001-5256.2018.04.015
Abstract:
Objective To investigate the prevalence of minimal hepatic encephalopathy (MHE) in patients with hepatitis B cirrhosis.Methods A total of 105 patients with hepatitis B cirrhosis who visited Beijing Ditan Hospital, Capital Medical University, from June to December, 2012 were enrolled as cirrhosis group, and 105 healthy volunteers were enrolled as healthy control group.The number connection test (NCT) , Stroop color-word test (CWT) , and clock drawing test (CDT) were used to evaluate cognitive function.The t-test or the Wilcoxon rank-sum test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups.Results Compared with the healthy control group, the cirrhosis group had significantly longer time spent on NCT-A, NCT-B, CWT-A, CWT-B, and CWT-C (t =-2.158, -2.372, -2.063, -2.611, and-4.325, all P < 0.05) and a significantly lower score of CDT-1 (t = 2.884, P < 0.05) .Of all patients with hepatitis B cirrhosis, 46 (43.81%) were diagnosed with MHE, among whom 24 (22.86%) had an abnormal information processing speed, 17 (16.19%) had an abnormal reaction inhibition ability, 15 (14.29%) had an abnormal visuospatial ability, and 10 (9.52%) had an abnormal set-shifting ability.Conclusion There is a high detection rate of MHE in patients with hepatitis B cirrhosis and stable liver function, and a combination of neuropsychological tests can increase the detection rate of MHE.
Original articles_Liver neoplasms
Clinical effect and safety of transarterial chemoembolization combined with apatinib in treatment of advanced primary liver cancer
Wu Jian, Yin Fang, Luo GuanHong, Zheng YangYang, Li Hong, Zhu ShaoHua, Zhang Jing, Zhou XinMin
2018, 34(4): 775-778. DOI: 10.3969/j.issn.1001-5256.2018.04.016
Abstract:
Objective To investigate the clinical effect and safety of transarterial chemoembolization (TACE) combined with apatinib versus TACE alone in the treatment of advanced primary liver cancer (PLC) .Methods A retrospective analysis was performed for the clinical data of 56 patients with PLC who were admitted to Xijing Hospital of Air Force Medical University from March to August, 2015, and according to therapies, these patients were divided into observation group and control group, with 28 patients in each group.The patients in the observation group were given TACE combined with apatinib, and those in the control group were given TACE alone.The two groups were compared in terms of objective response rate (ORR) at 1, 3, 6, and 12 months after treatment, progression-free survival, and incidence rates of adverse reactions.The two-independent-samples t test was used for comparison of continuous data between groups; the chi-square test was used for comparison of categorical data between groups.The Kaplan-Meier method was used to analyze median progression-free survival and plot survival curves, and the log-rank test was used for survival difference analysis between the two groups.Results There was no significant difference in ORR at 1 and 3 months after treatment between the two groups (χ2= 0.312 and 2.450, P = 0.386 and 0.118) , while there was a significant difference in ORR at 6 and 12 months after treatment (χ2= 9.458 and 13.065, P = 0.002 and P < 0.001) .There was also a significant difference in progression-free survival between the two groups (χ2= 9.083, P = 0.006) .Compared with the control group, the observation group had significantly higher incidence rates of apatinib-related adverse reactions, such as hypertension, hand-foot syndrome, proteinuria, and diarrhea (χ2= 17.500, 16.095, 15.273, and 5.256, all P < 0.001) , and these adverse reactions were relieved after the symptomatic treatment.Conclusion Compared with TACE alone, TACE combined with apatinib has a better long-term effect and safety in the treatment of advanced PLC.
Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in treatment of rabbit VX2 liver tumors
Li Hao, Duan XuHua, Han XinWei, Ren JianZhuang, Li FengYao, Kuang DongLin, Li FangZheng
2018, 34(4): 779-783. DOI: 10.3969/j.issn.1001-5256.2018.04.017
Abstract:
Objective To investigate the clinical effect of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) (TACE + RFA) versus RFA or TACE alone in the treatment of rabbit VX2 hepatic tumors and related pathological changes.Methods The rabbits were sacrificed at 7 days after surgery, and the maximal diameter of coagulative necrotic zone or hemorrhagic infarct zone was compared, as well as typical pathological sections.An analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups.Results One rabbit in the RFA group died of pneumothorax and one in the TACE + RFA group died of extensive liver necrosis at 2 days after surgery.The other 16 rabbits survived to the end of observation, resulting in a success rate of 88.9% (16/18) .There were significant differences between the TACE + RFA group and the other two groups in the maximal long and short diameters of coagulative necrotic zone and tumor cell necrosis rate (all P < 0.05) .The pathological analysis revealed greater vascular thrombosis, larger necrotic zone, and fewer clusters of viable tumor cells in the TACE + RFA group, compared with the other groups.Conclusion TACE + RFA has a better effect in tumor destruction than RFA or TACE alone.
Effect of lobaplatin on proliferation and apoptosis of hepatocellular carcinoma HepG2 cells and related mechanism of action
Li YingYing, Zhan LiFen, Ceng ZheChao, Xu Shen
2018, 34(4): 784-788. DOI: 10.3969/j.issn.1001-5256.2018.04.018
Abstract:
Objective To investigate the effect of lobaplatin on the proliferation and apoptosis of hepatocellular carcinoma (HCC) HepG2 cells in vitro and related mechanism of action.Methods HepG2 cells were divided into lobaplatin group (proliferation assay:5 μmol/L, 10 μmol/L, and 15 μmol/L; apoptosis assay:10 μmol/L; invasion assay:4 μg/ml) and control group (no drug was added) .CCK-8 assay and flow cytometry were used to measure the proliferation and apoptosis of HepG2 cells.Western Blot was used to measure the change in the expression of NF-κB, Bcl-2, Bax, Bid, Puma, and caspase-3 proteins involved in proliferation and apoptosis.A two-way analysis of variance was used for proliferation assay, the chi-square test was used for apoptosis assay, and the t-test was used for invasion assay.Results After intervention for 24, 48, and 72 hours, there was a significant difference in proliferation inhibition rate between the two groups (F = 273.5, P < 0.01) ; there was also a significant difference between different concentration groups at the same time point (F =1857, P < 0.01) , and all the concentration groups showed a significant change over time (F = 1365, P < 0.01) .As for apoptosis, there was a significant difference in apoptosis rate between the two groups (χ2= 1821, P < 0.001) .As for invasion ability, compared with the control group, the lobaplatin group had a significantly lower number of cells passing through the Transwell chamber (21.30 ± 2.74 vs 45.00± 4.26, t = 11.89, P < 0.001) .As for proteins, the lobaplatin group had a significant reduction in the expression of Bcl-2 and significant increases in the expression of NF-κB, Bax, Puma, and caspase-3.Conclusion Lobaplatin exerts a certain effect on the proliferation and apoptosis of HCC HepG2 cells by affecting the proteins involved in proliferation and apoptosis, but further studies are needed due to complex signaling pathways in cells.
Original articles_Biliary diseases
Risk factors for gallstones in Tibetan Plateau
Yang Bo, Hou YongZhi, Wang XiangFei, De Ji, Bin YeJian, Bai Zhen, Mi Ma
2018, 34(4): 789-794. DOI: 10.3969/j.issn.1001-5256.2018.04.019
Abstract:
Objective To investigate the risk factors for gallstones in Tibetan Plateau.Methods A total of 254 patients who underwent ultrasound examination in a fasting state in Shigatse People's Hospital from April 1 to 15, 2017 were enrolled, and according to the results of ultrasound examination, these patients were divided into gallstone group with 45 patients and control group with 209 patients.A questionnaire survey, a physical examination, and a result analysis were performed for all patients.The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups; a logistic regression analysis was performed to identify risk factors for gallstones.Results There were significant differences between the gallstone group and the control group in 15 variables including age, drinking amount of Tibetan butter tea, systolic pressure, sex, ethnicity, education level, smoking, a history of inherited diseases, and HBs Ag (all P < 0.05) .The univariate and multivariate analyses showed that female sex (odds ratio [OR]= 3.765, 95% confidence interval [CI]:1.742-8.138) , a history of inherited diseases (OR = 5.995, 95% CI:1.666-21.580) , a low education level (OR = 2.907, 95% CI:1.342-6.295) , systolic pressure (OR = 1.022, 95% CI:1.004-1.041) , and drinking amount of Tibetan butter tea (OR = 1.082, 95% CI:1.007-1.163) were independent risk factors for gallstones in Tibetan Plateau (all P < 0.05) .Conclusion Sex, drinking amount of Tibetan butter tea, genetic factors, education level, and systolic pressure may be associated with the development of gallstones in Tibetan Plateau, which provides important information and clues for the prevention, early diagnosis, and treatment of gallstones in this area.
Original articles_Others
Clinical effect of integrated traditional Chinese and Western medicine therapy in patients with hepatitis B virus-related acute-on-chronic liver failure complicated by hepatic encephalopathy
Gong Man, Zhou Chao, Zhang Ning, Sun KeWei, Zhang ZhenGang, Li HanMin, Li XiuHui, Yang HongZhi, Li Qin, Wang Lin, Zhou XiaoZhou, Mao DeWen, Guo JianChun, Zhuo YunHui, Wang XianBo, Deng Xin, Wang JieFei, Cao WuKui, Zhang ShuQin, Zhang MingXiang, Li Yun
2018, 34(4): 795-800. DOI: 10.3969/j.issn.1001-5256.2018.04.020
Abstract:

Objective To investigate the 8-week mortality rate of patients with hepatitis B virus (HBV) -related acute-on-chronic liver failure (ACLF) complicated by hepatic encephalopathy (HE) treated with integrated traditional Chinese and Western medicine therapy, as well as independent prognostic factors.Methods A total of 125 HBV-ACLF patients with HE who were admitted to 18 hospitals from January 2012 to February 2015 were enrolled and divided into trial group and control group using a randomized controlled design.The patients in the trial group were given integrated traditional Chinese and Western medicine therapy, and those in the control group were given Western medicine therapy alone.The 8-week mortality rate was observed for both groups.The t-test or the Mann-Whitney U test was used for comparison of continuous data between groups; the chi-square test was used for comparison of categorical data between groups; the Kaplan-Meier method and the log-rank test were used for survival analysis; the Cox proportional hazards regression model was used for the analysis of risk factors.Results The 8-week mortality rate was 27.5% in the trial group and 50.0% in the control group (χ2= 5.630, P = 0.018) , the median survival time was 41.2 days in the trial group and 28.4 days in the control group, and the 8-week cumulative probability of survival was 60.4% in the trial group and 32.5% in the control group (χ2= 6.187, P = 0.013) .The Cox regression analysis showed that compared with the control group, the trial group was a protective factor in patients with HBV-ACLF complicated by HE (hazard ratio [HR]= 0.424, 95% confidence interval [CI]:0.208-0.864, P = 0.018) .There were significant differences between the two groups in total bilirubin (TBil) (HR = 1.063, 95% CI:1.002-1.128, P = 0.042) , prothrombin activity (PTA) (HR = 0.942, 95% CI:0.890-0.998, P = 0.044) , ACLF stage (HR = 2.737, 95% CI:1.287-5.818, P = 0.009) , and the presence or absence of gastrointestinal hemorrhage (HR = 5.291, 95% CI:1.736-16.126, P = 0.003) .Conclusion Traditional Chinese medicine treatment can significantly reduce the 8-week mortality rate of HBV-ACLF patients with HE, increase their 8-week survival probability, and prolong survival time.TBil, PTA, ACLF stage, and gastrointestinal hemorrhage are independent prognostic factors.

Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure
Gu Jing, Wang Yan, Chen Li, Xu Ying, Gan JianHe
2018, 34(4): 801-805. DOI: 10.3969/j.issn.1001-5256.2018.04.021
Abstract:

Objective To investigate the changes in the serum levels of interleukin-32 (IL-32) and interleukin-10 (IL-10) and their clinical significance in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) .Methods A total of 38 HBV-ACLF patients who were hospitalized and treated in The First Affiliated Hospital of Soochow University from September 2012 to March 2014 were enrolled as HBV-ACLF group, as well as 20 patients with chronic hepatitis B (CHB) (CHB group) and 20 healthy controls (healthy control group) .ELISA was used for dynamic monitoring of the changes in the serum levels of IL-32 and IL-10.The serum levels of IL-32 and IL-10 were compared between early-, middle-, and late-stage HBV-ACLF groups, between infection group and non-infection group, and between survival group and death group.The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for further comparison between two groups.Results Compared with the CHB group and the healthy control group, the HBV-ACLF group had significantly higher levels of IL-32 (500.98 ± 152.33 pg/ml vs 281.72 ± 99.28 pg/ml and 178.16 ± 50.54 pg/ml, both P < 0.05) and IL-10 (4.82 ± 1.03 pg/ml vs3.15 ± 0.98 pg/ml and 1.62 ± 0.43 pg/ml, both P < 0.05) .Dynamic monitoring of IL-32 level in the HBV-ACLF group showed that the early-stage HBV-ACLF group had a significantly higher level than the middle-stage HBV-ACLF group (540.69 ± 155.71 pg/ml vs 498.43 ± 135.56 pg/ml, P < 0.05) , and the middle-stage HBV-ACLF group had a significantly higher level than the late-stage HBV-ACLF group (498.43 ± 135.56 pg/ml vs 450.77 ± 102.33 pg/ml, P < 0.05) ; as for the level of IL-10, the early-stage HBV-ACLF group had a significantly lower level than the middle-stage HBV-ACLF group (1.94 ± 0.44 pg/ml vs 2.83 ± 0.97 pg/ml, P < 0.05) , and the middle-stage HBV-ACLF group had a significantly lower level than the late-stage HBV-ACLF group (2.83 ± 0.97 pg/ml vs 3.69 ± 1.23 pg/ml, P < 0.05) .The HBV-ACLF infection group had a significantly higher level of IL-32 than the non-infection group (553.41 ± 158.65 pg/ml vs 482.54 ± 110.16 pg/ml, P = 0.021) .Compared with the HBV-ACLF death group, the HBV-ACLF survival group had a significantly lower level of IL-32 (481.95 ± 100.67 pg/ml vs 540.62 ± 112.45 pg/ml, P = 0.011) and a significantly higher level of IL-10 (4.21 ± 1.27 pg/ml vs 3.61 ± 1.05 pg/ml, P = 0.038) .Conclusion The cytokine network plays an important role in the pathogenesis of HBV-ACLF.Serum IL-32 and IL-10 may be involved in disease progression, and dynamic monitoring of their levels helps with prognostic prediction.

Expression of M30 and CCL20 in serum in patients with HBV-related acute-on-chronic liver failure and their clinical significance
Chen HaiOu, Liu Shi, Lin YiHe
2018, 34(4): 806-809. DOI: 10.3969/j.issn.1001-5256.2018.04.022
Abstract:

Objective To investigate the serum levels of M30 and CCL20 and their association with short-term (3-month) prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) , as well as their clinical significance.Methods A total of 51 patients with HBV-ACLF who were diagnosed and treated in Hunan Provincial People's Hospital from October 2014 to January2017 were enrolled as HBV-ACLF group; 30 patients with chronic hepatitis B (CHB) who were hospitalized or followed up in the outpatient service were enrolled as CHB group; 30 healthy individuals who underwent physical examination were enrolled as control group.The patients with HBV-ACLF were followed up for 3 months, and according to the results of follow-up, these patients were divided into survival group and death group.ELISA was used to measure the serum levels of M30 and CCL20 in peripheral blood before treatment and after two weeks of treatment.The t-test was used for comparison of continuous data between two groups, and an analysis of variance was used for comparison between multiple groups.Results There were significant differences in the serum levels of M30 and CCL20 before treatment between the HBV-ACLF group, the CHB group, and the control group (M30:591.54 ± 262.06 U/L vs 241.58 ± 120.33 U/L vs 114.35 ±52.09 U/L, F = 22.75, P < 0.05; CCL20:386.51 ± 55.12 pg/ml vs 177.11 ± 27.51 pg/ml vs 33.95 ± 11.62 pg/ml, F = 51.47, P <0.05) .After two weeks of treatment, the HBV-ACLF death group had a significantly higher level of M30 than the HBV-ACLF survival group (648.17 ± 285.55 U/L vs 426.43 ± 217.64 U/L, t = 2.37, P < 0.05) and a significantly lower level of CCL20 than the HBV-ACLF survival group (232.28 ± 39.28 pg/ml vs 352.29 ± 52.43 pg/ml, t =-2.35, P < 0.05) .After 2 weeks of treatment, there were significant differences in the change rates of the serum levels of M30 and CCL20 between the two groups (M30:0.08 ± 0.04 vs 0.27 ± 0.12, t =2.49, P < 0.05; CCL20:0.39 ± 0.06 vs 0.11 ± 0.02, t = 2.54, P < 0.05) .Conclusion Patients with HBV-ACLF have significant increases in the serum levels of M30 and CCL20, which can accurately reflect cell apoptosis and inflammation in the liver.Patients with a significant reduction in CCL20 during treatment tend to have high mortality, and patients with a significant reduction in M30 tend to have good prognosis.Dynamic changes in M30 and CCL20 levels have a certain value in predicting the short-term prognosis of patients with HBV-ACLF.

Clinical significance of platelet count and its dynamic change in patients with acute-on-chronic liver failure
Xu ShanShan, Wei XinHuan, Lin Wei, Zhang Jing
2018, 34(4): 810-813. DOI: 10.3969/j.issn.1001-5256.2018.04.023
Abstract:

Objective To investigate the dynamic change of platelets in patients with acute-on-chronic liver failure (ACLF) , the association of platelet count and its change with patients' prognosis, and the cause of thrombocytopenia, since severe thrombocytopenia is often seen in patients with liver failure.Methods A total of 54 patients with ACLF who were hospitalized in Beijing You' an Hospital, Capital Medical University, from September 2014 to September 2016 were enrolled, and their clinical data were collected.An automatic blood analyzer was used to measure platelet count, and ELISA was used to measure the level of thrombopoietin (TPO) .The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups.The univariate and multivariate logistic regression analyses were used for prognostic parameters, and the receiver operating characteristic (ROC) curve was used to analyze the value of the change in platelet count in the diagnosis of liver failure.Results A total of 18 ACLF patients died before discharge, resulting in a mortality rate of 33.3%.These patients had a mean platelet count of 80.0 × 109/L [range (36.0-334.0) ×109/L], which was significantly lower than the normal value.The death group had a significantly greater reduction in platelet count than the survival group [ (-43.4 ± 58.9) × 109/L vs (-11.5 ± 29.1) × 109/L, t =-2.827, P = 0.041].With -27.5 × 109/L as the cut-off value of the change in platelet count, there was a significant difference in mortality rate between the platelet count change >-27.5 × 109/L group and the platelet count change ≤-27.5 × 109/L group (22.2% vs 72.2%, χ2= 12.623, P < 0.01) .The univariate analysis showed that platelet change, prothrombin time activity, and fasting blood glucose were influencing factors for patients' prognosis, and the multivariate analysis showed that platelet change was an independent influencing factor for the prognosis of ACLF patients, with an area under the ROC curve of0.743.The plasma level of TPO was measured for 24 patients, among whom 8 died before discharge, resulting in a mortality rate of 33.3%.There was no significant difference in the level of TPO between the survival group and the death group (91.8 ± 39.8 pg/ml vs 93.3 ± 46.5 pg/ml, t = 0, P = 0.938) .Conclusion Baseline platelet count in ACLF patients is significantly lower than the normal value.The reduction in platelet count is an independent risk factor for death before discharge in ACLF patients.Thrombocytopenia may not be associated with the reduction in TPO.

Distribution features of TCM syndrome types and syndrome elements of primary biliary cholangitis:a literature review
Zheng YueQi, Chen JianJie, Chen YiYun, Shi Zhen, Xu Li
2018, 34(4): 814-819. DOI: 10.3969/j.issn.1001-5256.2018.04.024
Abstract:

Objective To investigate the distribution features of traditional Chinese medicine (TCM) syndromes types and syndrome elements of primary biliary cholangitis (PBC) via literature research, and to provide a basis for further research on PBC syndromes and features.Methods CNKI, CBM, CQVIP, Wanfang Data, and Pub Med were searched for articles on PBC published up to August 31, 2017.Note Express2.0 was used for the screening of articles on PBC syndromes, and SPSS19.0 was used for statistical analysis.Results A total of 11 articles with 849 cases were included, and 19 PBC syndrome types and 18 syndrome elements were identified.A statistical analysis was performed from the aspects of the frequency of syndromes and the constituent ratio of cases, and the results showed that the core syndrome types of PBC were liver-kidney yin deficiency syndrome and the syndrome of stagnation of liver qi and spleen deficiency; major syndrome elements of disease location were the liver, the spleen, and the kidney; major syndrome elements reflecting the nature of disease included qi deficiency, dampness, yin deficiency, qi stagnation, blood stasis, and heat.Major syndrome types in the clinical symptom stage included stagnation of liver qi and spleen deficiency, liver-kidney yin deficiency, and deficiency of spleen qi and stomach qi, and major syndrome elements reflecting the nature of disease included qi deficiency, qi stagnation, yin deficiency, and dampness.Major syndrome types of decompensated cirrhosis included liver-kidney yin deficiency, deficiency of liver and kidney, and dampness and blood stasis; major syndrome elements of disease location were the liver and the kidney; major syndrome elements reflecting the nature of disease included yin deficiency, dampness, blood stasis, and deficiency of essence.Conclusion Distribution features of common syndrome types and syndrome elements of PBC summarized in this article lay a foundation for the development of the standards for TCM syndrome differentiation of PBC.

Association between the rapidity of response and progression to cirrhosis in patients with autoimmune hepatitis
Zhang HongXia, Guo LiPing, Zhou Lu, Wang BangMao
2018, 34(4): 820-824. DOI: 10.3969/j.issn.1001-5256.2018.04.025
Abstract:

Objective To evaluate the association between the rapidity of response and progression to cirrhosis in patients with autoimmune hepatitis (AIH) , and to analyze the influencing factors for the rapidity of response.Methods A retrospective analysis was performed on 61 AIH patients with long-term follow-up, who visited The General Hospital of Tianjin Medical University from November 2001 to May 2017.These patients were divided into five groups according to the time for transaminase to decrease to a normal level:< 3 months group, 3-6 months group, 6-12 months group, 12-24 months group, and > 24 months group.The chi-square test was used to compare the rate of progression to cirrhosis and sustained response rate between these groups.One-way analysis of variance and the two-independent-samples t test were used to analyze the influencing factors for the rapidity of response.The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups, and one-way analysis of variance was used for comparison between multiple groups; the chi-square test was used for comparison of categorical data between two groups, and the contingency table chi-square test was used for comparison between multiple groups.Results The < 3 months group had the lowest proportion of patients with progression to cirrhosis (20%) ; all of the two patients in the > 24 months group progressed to cirrhosis; and 62.5% of the patients in the 12-24 months group progressed to cirrhosis.The rate of progression to cirrhosis was significantly lower in the patients who showed response within 3 months than in those who showed no response within 3 months (20% vs 48.15%, χ2= 5.067, P < 0.05) .The rates of progression to cirrhosis for the < 3 months group, 3-6 months group, 6-12 months group, 12-24 months group, and > 24 months group were 20%, 41.7%, 20%, 62.5%, and 100%, respectively, and the < 3 months group had a significantly lower rate of progression to cirrhosis than the 12-24 months group and > 24 months group (χ2= 5.546 and 6.400, both P < 0.05) .The sustained response rate of the < 3 months group was significantly higher than that of the 12-24 months group and > 24 months group (χ2= 4.322, P < 0.05) .Conclusion For AIH patients, the rapidity of response is associated with progression to cirrhosis; a rapid response reduces the rate of progression to cirrhosis.Responding within 3 months may indicate a good outcome, while responding beyond 1 year may indicate a poor outcome.Initial alanine aminotransferase level, and therapeutic drugs may influence the rapidity of response.

A clinical study of pulmonary function changes in patients with nonalcoholic fatty liver disease
Chen ZhiHui, Zhang ShiRong, Sun WenJing, Wen LiangZhi, Liu KaiJun, Guo Yan, Wei YanLing, Wang Bin, Gu XiaoHong, Chen DongFeng
2018, 34(4): 825-828. DOI: 10.3969/j.issn.1001-5256.2018.04.026
Abstract:

Objective To investigate the pulmonary function changes in patients with nonalcoholic fatty liver disease (NAFLD) and their clinical significance.Methods A total of 275 NAFLD patients who underwent physical examination in Physical Examination Center of Daping Hospital, Army Medical University, from September 2016 to May 2017 were enrolled as NAFLD group, and 276 non-NAFLD patients were enrolled as control group.Pulmonary function data were analyzed for both groups, including forced vital capacity (FVC) , forced expiratory volume in the first second (FEV1) , and FEV1/FVC ratio, and pulmonary function parameters were compared between NAFLD patients with elevated alanine aminotransferase (ALT) and those with normal ALT.The two-independent-samples t test was used for comparison of continuous data with homogeneity of variance between groups, and the non-parametric Wilcoxon rank-sum test was used for comparison of continuous data with heterogeneity of variance between groups.The chi-square test was used for comparison of categorical data between groups.Results Compared with the control group, the NAFLD group had significantly lower FVC (3.60 ± 0.87 L vs 3.87 ± 0.80 L, t =-3.78, P < 0.01) and FEV1 (2.97 ± 0.79 L vs 3.17 ± 0.82 L, t =-2.87, P < 0.01) .The NAFLD group had a slightly lower FEV1/FVC ratio than the control group (82.06% + 13.88% vs 82.88% ± 13.0%, P > 0.05) .Compared with those with normal ALT, the NAFLD patients with elevated ALT had lower FVC (3.53 ± 0.82 L vs 3.69 ± 0.92 L, P > 0.05) , FEV1 (2.72 ± 0.80 L vs 3.06 ± 0.79 L, P > 0.05) , and FEV1/FVC ratio (81.21% ± 13.00% vs 82.69% ± 12.92%, P > 0.05) .Conclusion NAFLD patients may have pulmonary function damage, which may be associated with metabolic disorder and liver inflammation.

Effect of liver-regulating and spleen-strengthening method on lipid metabolism and expression of microtubule-associated protein light chain 3B in a rat model of nonalcoholic fatty liver disease
Li ZhangXin, Zhou Tao, Niu KeMin, Chen Jing, Wei BeiHai, Wang Jia, Meng SiHong, Li QinNa, Zheng Jiao, Shen QingYan, Chen RuiLin
2018, 34(4): 829-835. DOI: 10.3969/j.issn.1001-5256.2018.04.027
Abstract:

Objective To investigate the effect of the liver-regulating and spleen-strengthening method on lipid metabolism and expression of microtubule-associated protein light chain 3 B (LC3B) in a rat model of nonalcoholic fatty liver disease (NAFLD) , as well as the mechanism of this method in the treatment of NAFLD.Methods A total of 30 clean male Sprague-Dawley rats were randomly divided into control group, model group, and liver-regulating and spleen-strengthening group, with 10 rats in each group.The rats in the model group and the liver-regulating and spleen-strengthening group were given high-fat diet for 12 weeks.The rats in the liver-regulating and spleen-strengthening group were given liver-regulating and spleen-strengthening prescription 2 ml·100 g-1·d (five times the dose for adults) by gavage, and those in the control group were given normal diet and an equal volume of normal saline by gavage.The rats were sacrificed at the end of week 12, and blood and liver samples were collected to measure the serum levels of alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , triglyceride (TG) , total cholesterol (TC) , high-density lipoprotein cholesterol (HDL-C) , and low-density lipoprotein cholesterol (LDL-C) .HE staining was performed to observe hepatic steatosis, and immunohistochemistry was used to measure the change in the expression of LC3B in liver tissue.A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups; the Kruskal-Wallis H test was used for comparison of ranked data between multiple groups, and the Mann-Whitney U test was used for further comparison between two groups.Results HE staining showed that there were significant differences in the degree of hepatocyte fatty degeneration and score of inflammatory activity between the model group and the control group (both P < 0.001) ; compared with the model group, the liver-regulating and spleen-strengthening group had significant reductions in the degree of hepatocyte fatty degeneration and score of inflammatory activity (both P < 0.01) .Compared with the control group, the model group had significant increases in the serum levels of ALT, AST, TG, TC, HDL-C, and LDL-C (all P < 0.001) ; compared with the model group, the liver-regulating and spleen-strengthening group had significant reductions in the serum levels of ALT, AST, TG, TC, and LDL-C (all P < 0.05) .Compared with the control group, the model group had a slight increase in the expression of LC3B in liver tissue (χ2= 1.250, P > 0.05) ; compared with the model group, the liver-regulating and spleen-strengthening group had a significant increase in the expression of LC3B in liver tissue (χ2= 5.051, P < 0.05) .Conclusion The liver-regulating and spleen-strengthening method can improve liver function and blood lipids in experimental male Sprague-Dawley rats with NAFLD, possibly by increasing the level of autophagy in liver tissue.

Clinical features of patients with hepatic amyloidosis
Yu SiMiao, Wang YaChao, Zhu Yun, Wang LiFu, Du Ning, Sun YongQiang, Xu WenTao, Wang LiPing, Jing Jing, Zhang Fan, Wang RuiLin
2018, 34(4): 836-839. DOI: 10.3969/j.issn.1001-5256.2018.04.028
Abstract:

Objective To investigate the clinical features of patients with hepatic amyloidosis.Methods A retrospective analysis was performed for the clinical data of 12 patients with hepatic amyloidosis who were hospitalized in Department of Hepatology, 302 Hospital of PLA, from January 2011 to December 2016, including general information, clinical symptoms, signs, laboratory findings, imaging features, and pathological features.Results Of all 12 patients, there were 11 male patients (91.7%) and 1 female patient (8.3%) , aged 40-67 years (mean 53.0 ± 8.5 years) , and 2 (16.7%) had AA hepatic amyloidosis and 10 (83.3%) had AL hepatic amyloidosis.Major clinical symptoms included weakness in 7 patients (58.3%) , poor appetite in 5 patients (41.7%) , hepatic discomfort and pain in 9 patients (75.0%) , and proteinuria in 8 patients (66.7%) .Imaging examination showed liver cirrhosis in 12 patients (100%) , hepatomegaly in12 patients (100%) , and splenomegaly in 8 patients (66.7%) .Laboratory examination showed reduced albumin in 8 patients (66.7%) , abnormal liver function in 11 patients (91.7%) , increased total bilirubin in 7 patients (58.3%) , increased gamma-glutamyl transpeptidase (GGT) in 12 patients (100%) , and increased alkaline phosphatase (ALP) in 11 patients (91.7%) .Conclusion Hepatic amyloidosis mainly occurs in middle-aged men.The possibility of hepatic amyloidosis should be considered in case of liver cirrhosis, hepatomegaly, proteinuria, abnormal liver function, and increased ALP and GGT in clinical practice.Liver biopsy helps to make a definite diagnosis.There are still no effective therapies for this disease, but early diagnosis and intervention and timely treatment of complications can improve patients' prognosis.

Case reports
A case of cardiogenic cirrhosis due to long-term hyperthyroidism
Ning XiuJing, He LiLi, Zhou Qi, Xue ShuWen, Ji HuiFan
2018, 34(4): 840-841. DOI: 10.3969/j.issn.1001-5256.2018.04.029
Abstract:
A case of low-grade mucinous cystic neoplasm of the liver
Wu Bo, Li LiangTao, Xuan ZhiLu, Liu Feng, Han KaiZe, Zhang Wei, Liu YaHui
2018, 34(4): 842-844. DOI: 10.3969/j.issn.1001-5256.2018.04.030
Abstract:
Acute extensive portal vein thrombosis with pulmonary embolism: a case report
Yan Xin, Song XinYue, Dong HongJing, Yan Qi, Zhao YouYou, Jin JingLan
2018, 34(4): 845-847. DOI: 10.3969/j.issn.1001-5256.2018.04.031
Abstract:
A case of severe coagulation disorder caused by cefoperazone sodium and sulbactam 
Fu Xing, Guo FengChang, Niu JunQi
2018, 34(4): 848-849. DOI: 10.3969/j.issn.1001-5256.2018.04.032
Abstract:
Upper gastrointestinal hemorrhage caused by splenic artery pseudoaneurysm rupture due to chronic pancreatitis: a case report
Qi WenLei, Zhang JianWei, Ji JingWei, Zhou JianPeng, Wei Feng, Du XiaoHong, Wang GuangYi
2018, 34(4): 850-852. DOI: 10.3969/j.issn.1001-5256.2018.04.033
Abstract:
Reviews
Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems
Zhang Xi, Li YongGuo
2018, 34(4): 853-857. DOI: 10.3969/j.issn.1001-5256.2018.04.034
Abstract:
Chronic hepatitis C can lead to end-stage liver diseases such as liver cirrhosis and hepatocellular carcinoma, and timely antiviral therapy is the key to improving prognosis.The emergence and development of direct-acting antiviral agents (DAAs) have brought great changes to the treatment of chronic hepatitis C.Nowadays the countries in the world are gradually entering or have entered the era of DAAs, and the approval of the DAAs in our country is late, which leads to a short time of clinical application and limited clinical data.With reference to the studies in foreign countries, this article reviews the representative DAAs and treatment regimens which are suitable for Chinese patients and discusses some existing problems.
Role of the nuclear factor-kappa B signaling pathway on the progress of hepatic fibrosis and the anti-fibrotic mechanism of traditional Chinese medicine
Zhu Hui, Ping Jian, Xu LieMing
2018, 34(4): 858-861. DOI: 10.3969/j.issn.1001-5256.2018.04.035
Abstract:
Nuclear factor-kappa B (NF-κB) plays an important role in various physiological and pathological processes by regulating gene expression, such as cell survival, growth, proliferation, activation, and apoptosis.In particular, the NF-κB signaling pathway has an important regulatory effect on the progression of hepatic fibrosis.This article reviews the structure and function of NF-κB, the regulatory effect of NF-κB on hepatocytes, Kupffer cells, and hepatic stellate cells in the progression of hepatic fibrosis, and the anti-fibrotic mechanism of traditional Chinese medicine by regulating the activity of the NF-κB signaling pathway.We also point out the complex interaction between NF-κB and various types of cells in certain diseases and emphasize the clinical significance of traditional Chinese medicine in inhibiting the activity of NF-κB and alleviating hepatic fibrosis.
Cellular mechanisms in liver fibrosis regression
Wang Lin, Liu XueEn, Zhuang Hui
2018, 34(4): 862-866. DOI: 10.3969/j.issn.1001-5256.2018.04.036
Abstract:

With the action of various chronic factors for liver injury, hepatic stellate cells (HSCs) are activated and transformed to myofibroblasts (MFBs) and then migrate to the injured part and secrete a large amount of extracellular matrix (ECM) .Excessive deposition of ECM in the liver causes liver fibrosis.The elimination of factors for liver injury or effective treatment helps to achieve liver fibrosis regression.This article introduces the types of cells involved in liver fibrosis regression.MFBs play an important role liver fibrosis regression via senescence, apoptosis, and inactivation; macrophages exert an anti-fibrosis effect by accelerating ECM degradation and inducing MFB senescence; liver sinusoidal endothelial cells help to achieve liver fibrosis regression by maintaining its normal phenotype; natural killer cells are involved in liver fibrosis regression by killing the early activated HSCs and senescent MFBs.

Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma
Wu Lei, Wang Su
2018, 34(4): 867-871. DOI: 10.3969/j.issn.1001-5256.2018.04.037
Abstract:
At present, transarterial chemoembolization (TACE) combined with sorafenib is commonly used for patients with advanced hepatocellular carcinoma (HCC) who have lost the opportunity for surgery, and yet no consensus has been reached on the specific therapeutic paradigm.This article reviews the treatment modes of TACE combined with sorafenib and their effect and safety in the treatment of HCC.It is pointed out that these treatment modes have their own advantages and disadvantages and await further clinical studies, in order to provide a reference for the treatment of patients with advanced HCC.
Research advances in molecular imaging of hepatocellular carcinoma
Liu Zhao, Ma WenTing, Zhang PengFei, Li JinKui, Xiao JianXi, Lei JunQiang
2018, 34(4): 872-876. DOI: 10.3969/j.issn.1001-5256.2018.04.038
Abstract:
Hepatocellular carcinoma (HCC) is one of the malignancies with high mortality, and early diagnosis of this disease will directly affect its treatment regimens and prognosis.At present, molecular imaging is not only the most advanced diagnostic and evaluation method, but also an important research direction for the early diagnosis of HCC.This article introduces the definition and significance, as well as basic steps, of molecular imaging and discusses related targets in HCC imaging and the future direction of research on the molecular imaging of HCC.
New ideas and methods for the diagnosis and treatment of acute-on-chronic liver failure
Li ShanShan, Duan ZhongPing, Chen Yu
2018, 34(4): 877-882. DOI: 10.3969/j.issn.1001-5256.2018.04.039
Abstract:
Acute-on-chronic liver failure (ACLF) is commonly seen in China and has a complex pathogenesis, difficult clinical treatment, and poor prognosis.ACLF has become a hot topic in the research on liver diseases in recent years.This article elaborates on the research advances in ACLF in China and foreign countries from the aspects of the definition, etiology, prognostic evaluation, and treatment regimens of ACLF, in order to provide new ideas and methods for clinical diagnosis and treatment, reduce mortality rate, and improve the clinical outcome of patients with ACLF.
Research advances in the pathogenesis of drug-induced liver injury
Wang HaiZhen, Li XiuHui
2018, 34(4): 883-887. DOI: 10.3969/j.issn.1001-5256.2018.04.040
Abstract:
In recent years, the number of drug-induced liver injury (DILI) cases is increasing year by year due to unreasonable drug use in clinical practice, unclear composition of healthcare products and dietary supplements, and a lack of drug safety knowledge, and DILI has become a major cause of liver failure and liver transplantation.DILI has complex pathogenesis, and medical institutions are paying more and more attention to DILI.Related animal and cell experiments are being conducted all over the world, and advances have been made in metabolic pathways, immune mechanism, mitochondrial abnormality, and genetics of DILI.In-depth research on various pathogeneses and their association helps to reveal the true pathogenesis of DILI.With reference to the articles on the pathogenesis of DILI in China and foreign countries, this article elaborates on the current research status of the pathogenesis of DILI and provides a reference for clinical treatment and basic research.
Association between periampullary duodenal diverticula and bile duct stones
Ji Sheng, Zhao LiBo, Liu Xu
2018, 34(4): 888-891. DOI: 10.3969/j.issn.1001-5256.2018.04.041
Abstract:
Endoscopic retrograde cholangiopancreatography helps to improve the diagnostic rate of periampullary duodenal diverticula.The importance of periampullary duodenal diverticula in clinical practice lies in its close association with bile duct stones, and different types of periampullary duodenal diverticula have different associations with the development and recurrence of bile duct stones.This article reviews the epidemiology, typing, pathogenesis, and treatment of periampullary duodenal diverticula and the association between different types of periampullary duodenal diverticula and the development and recurrence of bile duct stones, in order to provide a reference for the diagnosis and treatment of periampullary duodenal diverticula complicated by bile duct stones in future.
Research advances in clinical diagnosis and treatment of gallbladder internal fistula
Ye Nan, Liu ZhangAn
2018, 34(4): 892-895. DOI: 10.3969/j.issn.1001-5256.2018.04.042
Abstract:
Gallbladder internal fistula is a rare complication of the biliary system.A lack of specific clinical manifestations of gallbladder internal fistula results in a low preoperative diagnostic rate.Surgery remains the main treatment method for gallbladder internal fistula; however, it may cause injuries in adjacent organs and postoperative complications such as biliary fistula and intestinal fistula.Laparoscopic surgery has the advantages of little trauma, fast recovery, and mild pain and has become a new trend in the treatment of gallbladder internal fistula.This article reviews the pathogenesis, clinical manifestations, and diagnosis of gallbladder internal fistula, as well as the selection of treatment modalities.
Advances in the diagnosis and treatment of gallbladder dyskinesia in adults
Liu Bing, Shang PeiZhong
2018, 34(4): 896-899. DOI: 10.3969/j.issn.1001-5256.2018.04.043
Abstract:
Gallbladder dyskinesia (GD) mainly manifests as recurrent biliary colic, which may greatly affect the patient's work and life, but it is often neglected by clinical physicians due to negative results of ultrasound examination.This article introduces the latest advances in the diagnosis and treatment of GD, including etiology, clinical manifestations, diagnostic examinations, diagnostic criteria, and treatment methods.It is pointed out that typical symptoms of biliary colic, low gallbladder emptying fraction, and exclusion of organic lesions in the gallbladder are the key to the diagnosis of GD.Cholecystectomy remains the major treatment method for GD, and further studies are needed to clarify which patients can benefit more from cholecystectomy.
Mechanism of action of curcumin in treatment of pancreatic cancer
Yu ZeYuan, Wang KeShen, Ren YanXian, Luo ZhangJiang, Cao HongTai, Jiao ZuoYi
2018, 34(4): 900-904. DOI: 10.3969/j.issn.1001-5256.2018.04.044
Abstract:
Curcumin is a polyphenol extracted from the rhizome of Rhizoma Curcumae Longae with anti-inflammatory, antioxidant, and antitumor effects.It can also increase the sensitivity to chemoradiotherapy and protect hepatic and renal function.It is involved in the regulation of various signaling pathways and the expression of oncogenes and thus may become a potential anti-tumor drug for pancreatic cancer.This article reviews the mechanism of action of curcumin in inhibiting the proliferation and inducing the apoptosis of pancreatic cancer cells and inhibiting the signaling pathways involved in pancreatic cancer.